home LATEST ONCOPRESCRIBE UPDATES FDA Approves Tucatinib with Trastuzumab for Colorectal CancerFDA Approves BRUKINSA® for Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTAILORx Long Term Update for Patients with Early Stage Breast CancerSequential Conditioning and Allogeneic Hematopoietic Cell Transplantation WITHOUT Prior Remission-Induction Chemotherapy in AMLFDA Approves First Gene Therapy for Bladder CancerFDA Approves Bispecific Antibody LUNSUMIO® for Follicular LymphomaNeoadjuvant Chemotherapy, Endocrine Therapy and Targeted Therapy for Breast Cancer: ASCO Updated GuidelineTumor-Infiltrating Lymphocyte Therapy in Advanced Refractory Melanoma SHOW MORE FDAApprovals Meeting Updates Hem/OncUpdates Symptom Management NEW REGIMENS ADDEDResearch RegimensTIBSOVO® - for Acute Myeloid Leukemia Single Agent LUMAKRAS® - for Non Small Cell Lung CancerKEYTRUDA® - for Malignant Melanoma TECENTRIQ® and ABRAXANE® - for Breast CancerKEYTRUDA® plus INLYTA® - for Renal Cancer Curbside ConsultationRenal Cell Carcinoma Special IssueImmuno-OncologyPrecision OncologyCOVID-19 Associated Coagulopathy: Diagnosis and ManagementTTP, HUS and aHUS: Different diseases – Different treatmentsHER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateDual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal TumorsFDA Approves ENDARI®, A New Treatment for Sickle Cell DiseaseSHOW MORE